Complete enrollment of the second cohort for the AMT-260 study
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 May 2026
- Due
- 30 Jun 2026
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Enrollment of the second cohort is expected to be completed in mid-2026.”
What we found
Evidence strength A What the grades mean
The company stated in June 2026 that enrollment was ongoing and expected to be completed in mid-2026, but a July 2026 filing revised this expectation to the third quarter of 2026.
-
A uniQure N.V. 8-K filed 2026-06-22
“Enrollment is ongoing in a second, higher dose cohort (3x1012 gc/mL), expected to consist of six patients with enrollment anticipated to be completed mid-2026.” ✓ confirmed on the page
-
A uniQure N.V. 8-K filed 2026-07-29
“The Company expects to complete enrollment in the second dose cohort in the Phase I/IIa study in the third quarter of 2026.” ✓ confirmed on the page
Market reaction: the shares moved +18.2% against the S&P 500 over the three sessions around the disclosure (28 Jul 2026 to 31 Jul 2026). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- AMT-260 second cohort enrollment
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-QURE-001938 · Corrections policy